Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.
Pharmaceutical regulators and healthcare reimbursement authorities operate in different intellectual paradigms and adopt very different decision rules. As a result, drugs that have been licensed are often not available to all patients who could benefit because reimbursement authorities judge that the cost of therapies is greater than the health produced. This finding creates uncertainty for pharmaceutical companies planning their research and development investment, as licensing is no longer a guarantee of market access. In this study, we propose that it would be consistent with the objectives of pharmaceutical regulators to use the Net Benefit Framework of reimbursement authorities to identify those therapies that should be subject to priority review, that it is feasible to do so and that this would have several positive effects for patients, industry, and healthcare systems.
McCabe
Christopher
C
Leeds Institute of Health Sciences, UK. c.mccabe@leeds.ac.uk
Claxton
Karl
K
O'Hagan
Anthony
A
D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics / Q000458:organization & administration*; D004345:Drug Industry / Q000458:organization & administration; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics*; D011634:Public Health; D013673:Technology Assessment, Biomedical / Q000191:economics / Q000458:organization & administration*